FY2025 · ended Dec 31, 2025 · Revenue $44.56B, +3.9% YoY · Filed Feb 26, 2026
Thermo Fisher Scientific Inc. (TMO) files with the SEC under industry code 3829, Measuring & Controlling Devices, NEC. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $44.6 billion and net income of $6.7 billion. Free cash flow was $6.3 billion. As of Sep 26, 2026 it held $6.1 billion in cash and investments and $41.4 billion in total debt.
Revenue (TTM)
$47.35B
+8.3% vs year-ago TTM
Net income (TTM)
$7.07B
Operating cash flow (TTM)
$9.32B
+21.9% vs year-ago TTM
Free cash flow (TTM)
$7.60B
+24.3% vs year-ago TTM
EPS (TTM)
$18.93
Dividend per share (TTM)
$1.84
+9.5% vs year-ago TTM
Shares outstanding
371.48M
-1.5% vs prior year
Net cash
$-35.31B
as of Sep 26, 2026
Operating margin
17.9%
FY 2026
Company profile
- Industry
- Measuring & Controlling Devices, NEC (SIC 3829)
- Listed as
- TMO (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Waltham, MA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 97745
- Former names
- THERMO ELECTRON CORP (until Nov 3, 2006)
Other Measuring & Controlling Devices, NEC companies
- Rockwell Automation, Inc ROK
- Trimble Inc. TRMB
- Onto Innovation Inc. ONTO
- Mirion Technologies, Inc. MIR
- Quantum-Si Inc QSI
- Owlet, Inc. OWLT
- Geospace Technologies Corp GEOS
- Birchtech Corp. BCHT
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $44.6B | $42.9B | $42.9B | $44.9B | $39.2B |
| Operating income | $7.7B | $7.3B | $6.9B | $8.4B | $10.0B |
| Net income | $6.7B | — | — | — | — |
| Diluted EPS | $17.74 | $16.53 | $15.45 | $17.63 | $19.46 |
| Operating cash flow | $7.8B | $8.7B | $8.4B | $9.2B | $9.3B |
| Free cash flow | $6.3B | $7.3B | $6.9B | $6.9B | $6.8B |
| Total assets | $110.3B | $97.3B | $98.7B | $97.2B | $95.1B |
| Stockholders' equity | $53.4B | $49.6B | $46.7B | $44.0B | $40.8B |
| Cash and investments | $10.1B | $5.6B | $8.1B | $8.5B | $4.5B |
| Total debt | $40.9B | $32.8B | $36.4B | $36.1B | $36.3B |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change
|
Oct 30, 2026 | Oct 27, 2026 |
| 10-Q | Quarterly report | Oct 30, 2026 | Sep 26, 2026 |
| 8-K |
Current report
Results of operations
|
Oct 21, 2026 | Oct 21, 2026 |
| 10-Q | Quarterly report | Jul 31, 2026 | Jun 27, 2026 |
| 8-K |
Current report
Results of operations
|
Jul 23, 2026 | Jul 23, 2026 |
| 8-K |
Current report
Shareholder vote results
|
May 26, 2026 | May 20, 2026 |
All 1000 Thermo Fisher Scientific Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.